Lv71
4290 积分 2025-03-19 加入
The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus
1小时前
待确认
The occurrence, nature and distribution of flares in a cohort of patients with systemic lupus erythematosus: a rheumatological view
4小时前
待确认
BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus
4小时前
已完结
Interferon activation in primary Sjögren’s syndrome: recent insights and future perspective as novel treatment target
16天前
已完结
Design of Two Randomized, Placebo-Controlled, Phase 3 Trials of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Systemic Lupus Erythematosus
21天前
已关闭
First‐in‐human study of deucravacitinib: A selective, potent, allosteric small‐molecule inhibitor of tyrosine kinase 2
23天前
已完结
Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study
1个月前
已完结
Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study
1个月前
已完结
Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study
1个月前
已完结
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial
1个月前
已完结
皖公网安备34019202002308
